GLP-1 Refund

GLP-1 Refund

GLP-1 injury information

Request Review

Ozempic Overview

Reviewed April 2026

Ozempic: what the current label says, common side effects, and major warnings

Ozempic is a weekly semaglutide injection used with diet and exercise to improve glycemic control in adults with type 2 diabetes. Current labeling also includes cardiovascular and kidney-risk reduction language for some adults with type 2 diabetes and outlines common side effects and major warnings.

Request ReviewReview Sources

At A Glance

Current Ozempic labeling lists type 2 diabetes use plus cardiovascular and kidney-risk reduction indications in certain adults with type 2 diabetes.
The label says dose escalation is used to reduce the risk of gastrointestinal adverse reactions.
Common adverse reactions listed in current Ozempic labeling include nausea, vomiting, diarrhea, abdominal pain, and constipation.
If one issue clearly fits, use the page on that symptom or warning instead of this broader overview.

What Ozempic is prescribed for

The current Ozempic label says the medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The same label also includes reduction-of-risk language for major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and kidney-risk reduction language for certain adults with type 2 diabetes and chronic kidney disease.

This overview helps separate the general product information from narrower questions about vomiting, vision changes, or another specific warning topic.

References For This Section

DailyMed: Ozempic prescribing informationMedlinePlus: Semaglutide injection drug information

Why the dose usually starts low

The current label says treatment starts at 0.25 mg once weekly before increasing. It specifically explains that the dose-escalation schedule is used to reduce the risk of gastrointestinal adverse reactions.

That helps explain why early nausea, vomiting, abdominal discomfort, or constipation may show up during treatment. Persistent or severe symptoms still should not be dismissed.

References For This Section

DailyMed: Ozempic prescribing information

What the main warning sections cover

The current Ozempic label covers several major warning areas, including thyroid boxed-warning language, severe gastrointestinal adverse reactions, vision and retinopathy concerns, pancreatitis-type symptoms, and hypersensitivity reactions.

This page is an overview. If one of those issues is the real concern, the page devoted to that symptom or warning will usually be more useful.

References For This Section

DailyMed: Ozempic prescribing informationMedlinePlus: Semaglutide injection drug information

When To Seek Medical Care

  • Severe abdominal pain, repeated vomiting, dehydration, sudden vision changes, or possible allergic reactions should be evaluated promptly by a licensed clinician.
  • This page summarizes label language, but it is not a substitute for medical care.
  • If you are trying to document what happened, keep the product name, dose changes, symptom timeline, and clinician visits together.

FAQ

Is Ozempic the same thing as Wegovy?+

They are both semaglutide products, but they are not identical in branding, labeling context, and approved uses. When possible, document the exact product name that was prescribed.

Why have a broad Ozempic page if there are symptom-specific pages too?+

Because it gives the broad label context before you narrow down to one symptom, warning, or diagnosis.

Related Reading

Gastroparesis concerns

Coverage of persistent nausea, vomiting, early fullness, and delayed-gastric-emptying concerns.

Pancreatitis concerns

Useful when the question is severe abdominal pain, pain radiating to the back, or whether pancreatitis was evaluated.

Vision changes and retinopathy

A focused page for blurry vision, retinopathy concerns, and when prompt eye care matters.

Official References

The references below are the main public sources used for this page, usually current labeling plus agency or NIH material on symptoms, evaluation, or record access.